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Adaptive Servo-Ventilation for Central Sleep Apnea  
in Heart Failure
To the Editor: Cowie et al. (Sept. 17 issue)1 re-
port on the results of the Treatment of Sleep-
Disordered Breathing with Predominant Central 
Sleep Apnea by Adaptive Servo Ventilation in Pa-
tients with Heart Failure (SERVE-HF) trial. They 
found increases in all-cause and cardiovascular 
mortality among patients with heart failure who 
received adaptive servo-ventilation therapy, and 
the adaptive servo-ventilation group had no im-
provement in quality-of-life measures.
These results contradict those of our Study of 
the Effects of Adaptive Servo-ventilation Therapy 
on Cardiac Function and Remodeling in Patients 
with Chronic Heart Failure (SAVIOR-C).2 The 
majority of patients who received adaptive servo-
ventilation in our study had improvements in 
quality of life, and the improvement from New 
York Heart Association (NYHA) functional class 
III heart failure to class II heart failure was sig-
nificant.
We found that the adaptive servo-ventilation 
settings differed between the two studies. Cowie 
et al. manually increased the expiratory and in-
spiratory positive airway pressures from the de-
fault levels to suppress sleep apnea.1 Because the 
effects of positive airway pressure on cardiac out-
put depend on the baseline pulmonary-capillary 
wedge pressure,3 we were concerned that exces-
sive increases in levels of airway pressure might 
diminish cardiac output and induce reflex sym-
pathetic hyperactivity in some patients with mild 
pulmonary congestion. For this reason, the levels 
of airway pressure in patients in the SAVIOR-C 
were maintained at or below the default levels.2,4 
It would be useful to know whether high-pres-
sure adaptive servo-ventilation settings precipi-
tated adverse events in their patients.
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To the Editor: In the article by Cowie and col-
leagues about the use of adaptive servo-ventila-
tion in patients who had heart failure with re-
duced ejection fraction and sleep apnea, adaptive 
servo-ventilation was not beneficial with respect 
to the primary end point. In addition, all-cause 
and cardiovascular mortality were increased with 
this therapy.
Although adaptive servo-ventilation can work 
in the treatment of sleep apnea,1 when sleep 
apnea is associated with heart failure, the back-
ground physiology may be more complicated. 
Sleep apnea is accompanied by mouth breathing; 
this leads to loss of water and, eventually, it 
could cause dehydration. Appropriate physio-
logical responses to dehydration are drinking, 
vasopressin release, and activation of the renin–
angiotensin–aldosterone system (RAAS).2 Antago-
nists of the RAAS are mainstays of treatment for 
heart failure3 and are used in the majority of 
patients with sleep apnea.4 This suggests that 
patients with sleep apnea5 and patients with 
heart failure may both have severe dehydration.
Increased water intake to restore blood vol-
ume would reduce blood levels of angiotensin, 
vasopressin, and aldosterone. These decreased 
levels may decrease mortality among patients 
with heart failure who have sleep apnea.
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To the Editor: Cowie et al. report an increase 
in all-cause and cardiovascular mortality among 
patients with heart failure and predominantly 
central sleep apnea who received adaptive servo-
ventilation. It would be interesting to know the 
prevalence of pulmonary hypertension, right ven-
tricular failure, or both among patients in this 
study and whether these conditions were associ-
ated with an increased risk of death from any 
cause and death from cardiovascular causes. Pul-
monary hypertension and right ventricular fail-
ure are common complications of left heart fail-
ure and are associated with a poor prognosis.1
In addition, the presence of these conditions 
and the associated effect of positive pressure 
ventilation on the right ventricle may provide 
insight into the potential mechanism of the in-
creased all-cause and cardiovascular mortality 
observed in the adaptive servo-ventilation group. 
Positive pressure ventilation imposes a burden 
on the right ventricle by decreasing right ven-
tricular preload and increasing pulmonary vas-
cular resistance because of an increase in lung 
volume.2,3 This burden could potentially lead to 
worsening right ventricular function, which may 
translate into an increase in all-cause and car-
diovascular mortality in this subgroup.
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To the Editor: We would like more information 
regarding the SERVE-HF trial. Specifically, we 
think that the device may have provided excessive 
ventilation. In patients with compensated heart 
failure, the adaptive servo-ventilation device pro-
vided pressure support of 8.5 cm of water at re-
spiratory rates of 20 breaths per minute or more; 
this amounts to a minute ventilation of 10.2 liters 
per minute, which is double the normal value 
(assuming the lower limit of normal respiratory 
compliance). Patients with heart failure and cen-
tral sleep apnea have hypocapnia, with a conse-
quent predilection for arrhythmias during the 
hyperventilation phase of Cheyne–Stokes respi-
ration.1
We are concerned that the device algorithms 
that control rate and pressure support, com-
pounded by a minimum default pressure support 
of 3 cm of water, could have provided high min-
ute ventilation (up to 26.6 liters per minute). 
This high minute ventilation, in turn, may have 
contributed to life-threatening arrhythmias and 
death in the adaptive servo-ventilation group. 
Arrhythmia information from explanted pace-
makers or defibrillators from deceased patients, 
as well as information about minute ventilation 
from the adaptive servo-ventilation device, could 
shed more light on why there was an increased 
rate of deaths from cardiovascular causes with 
this treatment.
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To the Editor: The SERVE-HF investigators re-
port substantial nonadherence to the study pro-
tocol: at least 28% of the patients either discon-
tinued use of the trial device or never used it, and 
approximately 17% of the patients who were ran-
domly assigned to the control group crossed over 
to positive airway pressure therapy. Thus, without 
presenting an on-treatment analysis, the investi-
gators cannot conclude definitively that use of 
adaptive servo-ventilation places patients with cen-
tral sleep apnea at increased risk for death from 
any cause or death from cardiovascular causes.
Of the 666 patients who were randomly as-
signed to adaptive servo-ventilation, how many 
were adherent to adaptive servo-ventilation when 
they died, how many deaths occurred after pa-
tients abandoned its use, and how many deaths 
occurred in patients who were assigned to adap-
tive servo-ventilation but did not receive it? Simi-
lar data should be provided for the 659 control 
patients who were or were not receiving positive 
airway pressure ventilation when they died. 
Also, because any putative adverse hemodynam-
ic effect of positive intrathoracic pressure would 
dissipate once the mask is removed on awaken-
ing, would the investigators comment on wheth-
er participants were actually wearing the adap-
tive servo-ventilation mask when they died?
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To the Editor: In Germany, the Federal Insti-
tute for Drugs and Medical Devices (Bundesin-
stitut für Arzneimittel und Medizinprodukte 
[BfArM]) is the national authority responsible for 
the approval of clinical trials, collection of risk-
related data, and assessment of risks associated 
with the use of medical devices. At BfArM, we 
were formally notified about the results of the 
SERVE-HF trial by the trial sponsor (ResMed) in 
May 2015. Consequently, BfArM assumed a pri-
mary role in assessing subsequent corrective ac-
tions by various manufacturers.
In almost all reported subgroups, the rates of 
the primary end point (the first event of the 
composite of death from any cause, a lifesaving 
cardiovascular intervention, or an unplanned 
hospitalization for worsening chronic heart fail-
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ure) and cardiovascular death were higher in the 
adaptive servo-ventilation group than in the con-
trol group; we consider these increased rates to 
be serious concerns. Since the trial, specialist 
associations in Germany have recommended that 
adaptive servo-ventilation therapy should not be 
used in patients such as those enrolled in the 
SERVE-HF trial. The risk among all other pa-
tients remains unknown, and data from meta-
analyses, further clinical trials, or both are lacking.
However, we disagree with the conclusions 
expressed by Magalang and Pack1 in the edito-
rial accompanying the article. They suggest that 
patients with heart failure who have predomi-
nantly central sleep apnea are suitable candi-
dates for clinical trials. We have serious objec-
tions regarding the approval of such studies 
unless measures of risk reduction are identified. 
Ethical aspects of these studies have to be con-
sidered as well.
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The authors reply: In reply to Kihara et al.: 
in the SAVIOR-C, results from only 24 weeks of 
adaptive servo-ventilation therapy in 205 patients 
with heart failure were reported. Although there 
was a significant improvement in NYHA class, it 
was not accompanied by any difference in heart 
failure–related quality of life, left ventricular 
ejection fraction, or plasma levels of brain na-
triuretic peptide (BNP).1 In marked contrast to 
patients in the SERVE-HF trial, patients in the 
SAVIOR-C received adaptive servo-ventilation 
therapy irrespective of the presence or severity of 
sleep-disordered breathing. Such data cannot be 
directly compared with data from our study. We 
reported that throughout our trial the median 
inspiratory positive airway pressure was 10 cm of 
water (95th percentile, 14) and the median expi-
ratory positive airway pressure was 6 cm of water 
(95th percentile, 6); these pressures were similar 
to those in other studies of adaptive servo-venti-
lation that showed improvement in left ventricu-
lar ejection fraction, symptoms, or both. An 
analysis of the lack of association between ap-
plied pressures and events in our study is under 
way, although confounding by disease severity 
may be problematic.
In reply to Thornton et al.: on exploratory 
analysis, we found no association between 
markers of decreased intravascular volume and 
both the primary combined end point and car-
diovascular mortality. Although 85% of the pa-
tients were receiving a diuretic at baseline, the 
median of the furosemide-equivalent dose was 
only 40 mg (95% of the patients received a dose 
in the range of 10 to 300) per 24 hours. In addi-
tion, 56% of our patients used a humidifier with 
the adaptive servo-ventilation device. During the 
trial, we saw no difference between the two 
groups with respect to temporal trends in renal 
function (according to the estimated glomerular 
filtration rate) or hematocrit.
In reply to Hodges and Pilcher: although it 
has less power than the main study, a mechanis-
tic substudy has not shown an association be-
tween right ventricular function and the excess 
mortality in our trial. There was a positive asso-
ciation with pulmonary-artery pressure on uni-
variate analysis, but this effect was independent 
of adaptive servo-ventilation therapy and left 
ventricular ejection fraction.
We do not think that we provided excessive 
ventilation to patients, and we disagree with the 
calculation by Yamauchi et al., because the respi-
ratory system is less compliant in patients with 
heart failure than in patients without heart fail-
ure.2 Our algorithm achieves a moving target 
ventilation of 90% of the long-term average, 
thereby avoiding excessive ventilation. Elsewhere, 
we have shown that this algorithm is associated 
with only a very minor and statistically nonsig-
nificant drift in the partial pressure of carbon 
dioxide overnight (0.2 mm Hg).3
We agree with Bradley and Floras that on-
treatment analysis can be helpful, albeit with the 
challenges of the differential effects of selection 
and self-selection, the possibility of reverse cau-
sation, and larger random fluctuations in the 
data. The results of such an analysis do not 
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contradict the results of the intention-to-treat 
analysis.
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The editorialists reply: With respect to the 
comments by Schäfer and colleagues: we think 
that further investigation in this area is required, 
albeit with appropriate informed consent. There 
are at least two major unanswered questions. 
First, we do not know whether the results of the 
SERVE-HF trial were influenced by the specific 
adaptive servo-ventilation algorithm for adjust-
ment of positive pressure. An ongoing trial (Effect 
of Adaptive Servo Ventilation on Survival and Hos-
pital Admissions in Heart Failure [ADVENT-HF]; 
ClinicalTrials.gov number, NCT01128816) has 
different inclusion and exclusion criteria (it in-
cludes patients with both obstructive and central 
apneas) and uses a different adaptive servo-venti-
lation device with a less aggressive adjustment of 
positive pressure. The data and safety monitoring 
board for the ADVENT-HF trial has performed 
two interim analyses subsequent to the initial 
notification of the results of the SERVE-HF trial, 
and it has concluded that there are no safety con-
cerns (Bradley TD: personal communication).
Second, we do not know whether the risks 
and benefits of adaptive servo-ventilation are 
different in specific subgroups of patients with 
sleep-disordered breathing and congestive heart 
failure. Thus, we continue to think that further 
investigation of this topic is required.
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A Randomized, Controlled Trial of Total Knee Replacement
To the Editor: In the study reported by Skou 
and colleagues (Oct. 22 issue),1 patients were ex-
cluded if they had symptomatic knee osteoar-
thritis with pain scores higher than 60 mm on a 
visual-analogue scale (on which scores range 
from 0 to 100, with higher scores indicating 
worse pain). We are unclear as to the rationale 
for excluding patients with this level of pain, who 
are commonly seen in orthopedic practice. We 
agree with the conclusion that total knee replace-
ment is superior to the nonsurgical regimen in-
vestigated. However, we are concerned that the 
exclusion of 117 of 244 otherwise eligible patients 
(48%) because of severity of symptoms may have 
led to substantial underestimation of the effect 
sizes of treatments in both groups, especially in 
the surgical group because of potentially in-
creased crossover rates among the more severely 
symptomatic patients.
Reported serious adverse events (stiffness re-
quiring manipulation of the knee while the pa-
tient was under anesthesia and deep venous 
thrombosis requiring anticoagulation) both oc-
curred among 6% of patients in the total-knee-
replacement group. These rates were higher than 
the respective rates (1.3%2 and 1.5%3) reported 
elsewhere for much larger cohorts. The authors 
did not report the time-to-event end points, care 
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